Essence Parent to Acquire Esperion for $3.16/Share Cash, Plus CVR Up to $100M
ESPR has more than doubled off its 52-week low of $0.693 on elevated volume (17× avg).
Summary
Esperion Therapeutics has entered into a definitive agreement to be acquired by Essence Parent for $3.16 per share in cash, complemented by a Contingent Value Right (CVR) that could yield up to an additional $100 million based on future sales milestones. This announcement provides the crucial details of the previously undisclosed transaction that Esperion's Board of Directors had unanimously approved earlier today. The acquisition offers a premium to current shareholders and a clear exit strategy, fundamentally changing the investment thesis for the company. The deal is subject to stockholder and regulatory approvals and is expected to close in the third quarter of 2026, with the CVR linked to 2027 U.S. bempedoic acid product sales and future U.S. bumetanide product sales through 2030.
At the time of this announcement, ESPR was trading at $3.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $802.9M. The 52-week trading range was $0.69 to $4.18. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.